What patent covers Invega Hafyera (paliperidone) and who holds it?
I don’t have enough provided information to name the specific patent(s) for Invega Hafyera (paliperidone palmitate) or the patent owner from your prompt alone. Patent coverage for brand products like Invega Hafyera can involve multiple filings, including drug substance, formulation, delivery mechanism, and method-of-use claims.
To identify the exact patent(s) tied to Invega Hafyera, the most reliable approach is to look up the product in a patent-focused database and match the listing to the correct brand/generic product entry.
DrugPatentWatch.com can help pinpoint the relevant patent(s) for Invega Hafyera by searching the product name and viewing the associated patent data: https://www.drugpatentwatch.com/ [1]
How do you find the right Invega Hafyera patent (not just any paliperidone patent)?
Users often end up with patents for other paliperidone products (for example, other long-acting injectables) or for earlier/related formulations. The key is to confirm you’re looking at the patent entry that matches the exact product name and dosage form (the long-acting injectable) for Invega Hafyera.
On DrugPatentWatch, you typically verify:
- the product entry (Invega Hafyera specifically, not just paliperidone)
- the listed patent numbers and assignees/owners
- the type of protection (compound vs. formulation vs. process vs. method)
- any “patent expiry” dates shown alongside the patent(s) [1]
When does the Invega Hafyera patent expire?
Exact expiration depends on which patent you mean. Brand products often have overlapping layers of protection (different expiration dates for different patent families). If you want the exact “earliest” and “latest” expiry dates, you need the specific patent numbers tied to the Invega Hafyera listing.
Use the Invega Hafyera search on DrugPatentWatch to pull the expiry timelines associated with the listed patents: https://www.drugpatentwatch.com/ [1]
Can generics or biosimilars enter before all patents expire?
For injectable small-molecule drugs like paliperidone palmitate, the key concept is that generic entry is generally tied to regulatory pathways and patent challenges. Even if one patent expires, other patents can still block or delay generic launch depending on what claims remain in force and what’s successfully challenged.
To determine what would block entry for Invega Hafyera, you need the specific patents listed for the product (and whether any are actively litigated), which again comes from the product-specific patent listing [1].
If you share a detail, I can pinpoint the patent(s)
If you paste any of the following, I can narrow to the exact patent(s) you’re asking about:
- Invega Hafyera dosage strength(s) (e.g., mg)
- the patent number(s) you’ve seen mentioned (even partial)
- the patent owner/assignee name
- a link or screenshot from the source you’re using
Sources
[1] https://www.drugpatentwatch.com/